Evidence map›Paper›PMID 33523981›Full record

ArticleScience advances2021

ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism.

Rasmus Pihl, Rasmus K Jensen, Emil C Poulsen, Lisbeth Jensen, Annette G Hansen, Ida B Thøgersen, József Dobó, Péter Gál, Gregers R Andersen, Jan J Enghild and 1 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Rasmus PihlDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0003-1409-4135
Rasmus K JensenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-5472-4862
Emil C PoulsenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-7856-3386
Lisbeth JensenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Annette G HansenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Ida B ThøgersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
József DobóInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0001-9187-8502
Péter GálInstitute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary.ORCID 0000-0001-8987-2080
Gregers R AndersenDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Jan J EnghildDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.ORCID 0000-0001-9292-9172
Steffen ThielDepartment of Biomedicine, Aarhus University, Aarhus, Denmark. st@biomed.au.dk.ORCID 0000-0002-4817-155X
Aarhus University · DKInstitute of Molecular Life Sciences · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inter-α-inhibitor heavy chain 4 (ITIH4) is a poorly characterized plasma protein that is proteolytically processed in multiple pathological conditions. However, no biological function of ITIH4 has been identified. Here, we show that ITIH4 is cleaved by several human proteases within a protease-susceptible region, enabling ITIH4 to function as a protease inhibitor. This is exemplified by its inhibition of mannan-binding lectin-associated serine protease-1 (MASP-1), MASP-2, and plasma kallikrein, which are key proteases for intravascular host defense. Mechanistically, ITIH4 acts as bait that, upon cleavage, forms a noncovalent, inhibitory complex with the executing protease that depends on the ITIH4 von Willebrand factor A domain. ITIH4 inhibits the MASPs by sterically preventing larger protein substrates from accessing their active sites, which remain accessible and fully functional toward small substrates. Thus, we demonstrate that ITIH4 functions as a protease inhibitor by a previously undescribed inhibitory mechanism.

Identifiers

PMID33523981
PMCPMC7793589
OpenAlexW3119453444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.